Abstract:Background:This study sought to explore the biological significance of genetic variation in RAS wild-type metastatic colorectal cancer (mCRC) in the real world, the difference in the efficacy of cetuximab in the treatment of mCRC with different genetic variants and identify clinical features and new predictors of efficacy.Methods:A retrospective analysis of the data of 60 patients with stage IV mCRC who received cetuximab at The First and Second Affiliated Hospital of Soochow University from 2016 to 2020 was conducted. The patients were divided into the following 3 groups according to the genetic test results: (I) group A (the all-RAS wild-type group); (II) group B (the all-RAS wild-type group with the tumor suppressor gene mutation); and (III) group C (the all-RAS wild-type group with the oncogenic driver gene mutation). A subgroup analysis was conducted to examine left CRC and local intervention, and the progression-free survival (PFS) and overall survival (OS) of the patients were observed.Results:The all-RAS wild-type mCRC patients were divided into group A (n=10), group B (including the TP53, APC, PTEN, BRCA2, and SMAD4 variants) (n=42), and group C (including the ERBB2, BRAF, PIK3CA, and RET variants) (n=8). The median PFS of groups A, B, and C were 15.0, 12.0, and 3.0 months, respectively (P=0.007). Fitting sex as a stratified variable to the Cox survival analysis model showed that only the PFS of groups B and C differed significantly (P=0.011). In the left-sided mCRC patients, the median PFS of groups A, B, C were 3.0, 13.0, and 3.0 months, respectively (P=0.009). Among the patients in group B, the median PFS of the metastatic local intervention subgroup was 14.0 months, and the non-local intervention subgroup was 12.0 months (P=0.55). Only the type of combined gene mutation was an independent factor affecting PFS.Conclusions:The PFS and OS of mCRC patients with all-RAS wild-type and no combined mutations treated with cetuximab were not better than those of patients with combined mutations. Compared to mCRC patients with all-RAS wild-type and oncogenic driver gene mutations, cetuximab significantly prolonged the PFS of all-RAS wild-type patients with the tumor suppressor gene mutations.

Supplementary Table 1 from <i>pik3ca</i> Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer

Supplementary Table 4 from PIK3CA Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer

Supplementary Materials and Methods from <i>pik3ca</i> Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer

A Study of Gene Variation in All-RAS Wild-Type Metastatic Colorectal Cancer and Its Correlation with Cetuximab.

Figure S1, Table S1, Table S2 from KLF4 P.a472d Mutation Contributes to Acquired Resistance to Cetuximab in Colorectal Cancer

Supplementary Table S1 from <i>EGFR</i> Fluorescence <i>In situ</i> Hybridization Pattern of Chromosome 7 Disomy Predicts Resistance to Cetuximab in KRAS Wild-type Metastatic Colorectal Cancer Patients

Additional File 1: of SMAD4 and NF1 Mutations As Potential Biomarkers for Poor Prognosis to Cetuximab-Based Therapy in Chinese Metastatic Colorectal Cancer Patients

Identification and Prognostic Analysis of the Cetuximab Resistance-Related Gene REV1 in RAS Wild-Type Metastatic Colorectal Cancer.

Additional File 4: of SMAD4 and NF1 Mutations As Potential Biomarkers for Poor Prognosis to Cetuximab-Based Therapy in Chinese Metastatic Colorectal Cancer Patients

Supplementary Table 2 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC

Transcriptome Alterations In Liver Metastases Of Colorectal Cancer After Acquired Resistance To Cetuximab

Supplementary Table S1 from Germline <i>USP36</i> Mutation Confers Resistance to EGFR-TKIs by Upregulating MLLT3 Expression in Patients with Non–Small Cell Lung Cancer

Supplementary Table S2 from Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

Supplementary Table S4 from Germline <i>USP36</i> Mutation Confers Resistance to EGFR-TKIs by Upregulating MLLT3 Expression in Patients with Non–Small Cell Lung Cancer

Supplementary Table S2 from Germline USP36 Mutation Confers Resistance to EGFR-TKIs by Upregulating MLLT3 Expression in Patients with Non–Small Cell Lung Cancer

Supplementary Table S6 from Germline <i>USP36</i> Mutation Confers Resistance to EGFR-TKIs by Upregulating MLLT3 Expression in Patients with Non–Small Cell Lung Cancer

Supplementary Table S5 from Germline <i>USP36</i> Mutation Confers Resistance to EGFR-TKIs by Upregulating MLLT3 Expression in Patients with Non–Small Cell Lung Cancer

Supplementary Table S9 from Germline <i>USP36</i> Mutation Confers Resistance to EGFR-TKIs by Upregulating MLLT3 Expression in Patients with Non–Small Cell Lung Cancer

KLF4 p.A472D Mutation Contributes to Acquired Resistance to Cetuximab in Colorectal Cancer.

Data from <i>KLF4</i> p.A472D Mutation Contributes to Acquired Resistance to Cetuximab in Colorectal Cancer

Supplementary Figure 2 from Co-occurring EGFR P.e709x Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR P.g719x-Mutant Patients with Advanced NSCLC

Supplementary Table 1 from &lt;i&gt;pik3ca&lt;/i&gt; Mutations Contribute to Acquired Cetuximab Resistance in Patients with Metastatic Colorectal Cancer